http://orcid.org/0000-0001-7460-733X
Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Séverine Carillon, Gabrièle Laborde-Balen, Maïmouna Diop, Karim Diop, Guillaume Breton, Bara Ndiaye & Bernard Taverne. (2023) Implementing long-acting injectable antiretroviral treatments in Senegal: issues, challenges and conditions for introducing them. Qualitative study with healthcare providers and patients. AIDS Care 0:0, pages 1-7.
Read now
Read now
Karolina Akinosoglou, Stefania Antonopoulou, Ioannis Katsarolis & Charalambos A. Gogos. (2021) Patient-reported outcomes in HIV clinical trials evaluating antiretroviral treatment: a systematic review. AIDS Care 33:9, pages 1118-1126.
Read now
Read now
Casey D. Xavier Hall, Justin C. Smith, Robert A. Driggers, Bethany Stoller, Zara Khan, Jingjing Li, Elisa H. Ignatius & Aaron J. Siegler. (2021) PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia. AIDS Care 33:6, pages 706-711.
Read now
Read now
Sofía Scévola, Juan Manuel Tiraboschi & Daniel Podzamczer. (2020) Nothing is perfect: the safety issues of integrase inhibitor regimens. Expert Opinion on Drug Safety 19:6, pages 683-694.
Read now
Read now
Séverine Carillon, Lucille Gallardo, Françoise Linard, Catherine Chakvetadze, Jean-Paul Viard, Agnès Cros, Jean-Michel Molina & Laurence Slama. (2020) Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users’ ambivalences. AIDS Care 32:sup2, pages 155-161.
Read now
Read now
Lidija Kovač & Zdenko Časar. (2020) A literature review of the patent application publications on cabotegravir – an HIV integrase strand transfer inhibitor. Expert Opinion on Therapeutic Patents 30:3, pages 195-208.
Read now
Read now
Cristina Fernandez & Clare L van Halsema. (2019) Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS - Research and Palliative Care 11, pages 179-192.
Read now
Read now
Articles from other publishers (40)
John D Loaiza, Mateo Chvatal-Medina, Juan C Hernandez & Maria T Rugeles. (2023) Integrase inhibitors: current protagonists in antiretroviral therapy. Immunotherapy 15:17, pages 1477-1495.
Crossref
Crossref
Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, Suyash Deodhar, Srijanee Das, Ashrafi Sultana, Nam Thai Hoang Le, Vicente Soriano, Benson Edagwa & Howard E. Gendelman. (2023) Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Advanced Drug Delivery Reviews 200, pages 115009.
Crossref
Crossref
Aparna Alankar, Jamir Tuten, Travis Love, Jennifer Punsal, Shobha Swaminathan & Amesika N. Nyaku. (2022) HIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color. Journal of Racial and Ethnic Health Disparities 10:4, pages 1542-1548.
Crossref
Crossref
Dennis Feihel, Daniel Spier, Ty Stevens, Dimitre G. Stefanov & Ladan Ahmadi. (2022) Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals. AIDS and Behavior 27:7, pages 2370-2375.
Crossref
Crossref
Xiu Chen, Jun Li, Liqiu Kou, Xiaolu Xie, Deqing Wei & Yaling Li. (2023) Efficacy and safety of long‐acting cabotegravir versus oral tenofovir disoproxil fumarate‐emtricitabine as HIV pre‐exposure prophylaxis: A systematic review and meta‐analysis. Reviews in Medical Virology 33:4.
Crossref
Crossref
Sarah E. Stansfield, Jesse Heitner, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Brett Hanscom, Yiqing Xia, Mathieu Maheu‐Giroux, David van de Vijver, Haoyi Wang, Ruanne Barnabas, Marie‐Claude Boily & Dobromir T. Dimitrov. (2023) Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis. Journal of the International AIDS Society 26:S2.
Crossref
Crossref
Lara Lorenzetti, Nhi Dinh, Ariane van der Straten, Virginia Fonner, Kathleen Ridgeway, Michelle Rodolph, Robin Schaefer, Heather‐Marie A. Schmidt & Rachel Baggaley. (2023) Systematic review of the values and preferences regarding the use of injectable pre‐exposure prophylaxis to prevent HIV acquisition. Journal of the International AIDS Society 26:S2.
Crossref
Crossref
Sarah Y. Jenkins, Danielle Resar, Zachary Panos, Alan Staple, Melynda Watkins, David Ripin & Carolyn Amole. (2023) Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries. Journal of the International AIDS Society 26:S2.
Crossref
Crossref
Louis S. Matza, Timothy A. Howell, Vasiliki Chounta & Nicolas van de Velde. (2022) Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV. Quality of Life Research 32:2, pages 531-541.
Crossref
Crossref
Manya Magnus, Hannah Yellin, Kayley Langlands, Madhu Balachandran, Melissa Turner, Jeanne Jordan, Daniel Ramin, Irene Kuo & Marc Siegel. (2023) Overcoming structural barriers to diffusion of HIV pre-exposure prophylaxis. The Journal of Medicine Access 7.
Crossref
Crossref
Stanley E Cooper, Joshua Rosenblatt & Roy M Gulick. (2022) Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries. Clinical Infectious Diseases 75:Supplement_4, pages S541-S548.
Crossref
Crossref
Nguyen K. TranOmar MartinezAyden I. ScheimNeal D. GoldsteinSeth L. Welles. (2022) Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex With Men. AIDS Education and Prevention 34:5, pages 365-378.
Crossref
Crossref
Fabiana Volpe-Zanutto, Lalitkumar K. Vora, Ismaiel A. Tekko, Peter E. McKenna, Andi Dian Permana, Akmal H. Sabri, Qonita K. Anjani, Helen O. McCarthy, Alejandro J. Paredes & Ryan F. Donnelly. (2022) Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis. Journal of Controlled Release 348, pages 771-785.
Crossref
Crossref
Aravindh Nirmalan. (2022) Use of long-acting injectable cabotegravir and rilpivirine as an alternative for treatment in HIV positive patients. Clinical Research In Practice: The Journal of Team Hippocrates 8:1.
Crossref
Crossref
Morgan M. Philbin, Sadie Bergen, Carrigan Parish, Deanna Kerrigan, Elizabeth N. Kinnard, Sarah Reed, Mardge H. Cohen, Oluwakemi Sosanya, Anandi N. Sheth, Adaora A. Adimora, Jennifer Cocohoba, Lakshmi Goparaju, Elizabeth T. Golub, Michael Vaughn, José I. GutierrezJr.Jr., Margaret A. Fischl, Maria Alcaide & Lisa R. Metsch. (2021) Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most. AIDS and Behavior 26:4, pages 1260-1269.
Crossref
Crossref
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, Melanie Paff, William R. Spreen & Susan L. Ford. (2022) Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men. Antimicrobial Agents and Chemotherapy 66:3.
Crossref
Crossref
Sara H. Bares & Kimberly K. Scarsi. (2022) A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Current Opinion in HIV and AIDS 17:1, pages 22-31.
Crossref
Crossref
Olumuyiwa E Ariyo & Christopher E Jones. (2022) Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review. Journal of Clinical Virology 146, pages 105032.
Crossref
Crossref
Nwora Lance Okeke, Tony McLaurin, Ruth Gilliam-Phillips, David H. Wagner, Valerie J. Barnwell, Yolanda M. Johnson, Osaffo James, Padonda B. Webb, Sharon D. Parker, Bendu Hill, Mehri S. McKellar & John T. Mitchell. (2021) Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. BMC Public Health 21:1.
Crossref
Crossref
Babatunde Akinwunmi, Daniel Buchenberger, Jenny Scherzer, Martina Bode, Paolo Rizzini, Fabio Vecchio, Laetitia Roustand, Gaelle Nachbaur, Laurent Finkielsztejn, Vasiliki Chounta & Nicolas Van de Velde. (2021) Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries. Sexually Transmitted Infections 97:8, pages 566-573.
Crossref
Crossref
Panita Maturavongsadit, Gayane Paravyan, Martina Kovarova, J. Victor Garcia & S. Rahima Benhabbour. (2021) A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery. International Journal of Pharmaceutics: X 3, pages 100068.
Crossref
Crossref
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, Estelle Piwowar-Manning, Maoji Li, Lei Weng, Marybeth McCauley, Vanessa Cummings, Shahnaz Ahmed, Casey D Haines, Lane R Bushman, Christos Petropoulos, Deborah Persaud, Adeola Adeyeye, Ryan Kofron, Alex Rinehart, Marty St Clair, James F Rooney, Daniel Pryluka, Lara Coelho, Aditya Gaur, Keren Middelkoop, Nittaya Phanuphak, Myron S Cohen, Craig W Hendrix, Peter Anderson, Brett Hanscom, Deborah Donnell, Raphael J Landovitz & Susan H Eshleman. (2021) Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. The Journal of Infectious Diseases 224:9, pages 1581-1592.
Crossref
Crossref
Angela M. Heads, Mandy J. Hill, Robert Suchting, Luba Yammine & Adrienne Gilmore-Thomas. (2021) Predictors of Anticipated PrEP Stigma among Women with Self-Reported Problematic Substance Use: Implications for Engaging Women in the PrEP Care Continuum. Archives of Sexual Behavior 50:7, pages 2955-2964.
Crossref
Crossref
Richard Leong, Leon Owusu, Jerrica Tang, Neeraj John, Kira E Voyer, Emma Gargala, Benjamin Daigler, Qing Ma, Gene D Morse & Raymond Cha. (2021) Patient-reported outcomes for HIV: the future of long-acting injectables and antiretroviral therapy evaluations. Future Virology 16:8, pages 543-553.
Crossref
Crossref
Zach W. Howe, Sarah Norman, Abbie F. Lueken, Emily Huesgen, Eric K. Farmer, Kaitlyn Jarrell, Joscelyn E. Mathis, Kyle W. Bonham & Julie Hahn. (2021) Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:8, pages 686-699.
Crossref
Crossref
Terri L. Levien, Audrian Santos & Danial E. Baker. (2021) Formulary Drug Review: Cabotegravir. Hospital Pharmacy, pages 001857872110295.
Crossref
Crossref
Gilbert Lazarus, Vincent Kharisma Wangsaputra, Christianto, Melva Louisa, Vivian Soetikno & Raph L. Hamers. (2021) Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials. Frontiers in Pharmacology 12.
Crossref
Crossref
Daryl Hodge, David J. Back, Sara Gibbons, Saye H. Khoo & Catia Marzolini. (2021) Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics 60:7, pages 835-853.
Crossref
Crossref
Subhra Mandal, Pavan Kumar Prathipati, Shawnalyn W. Sunagawa & Christopher J. Destache. (2021) A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. Antimicrobial Agents and Chemotherapy 65:4.
Crossref
Crossref
Morgan M. Philbin, Carrigan Parish, Elizabeth N. Kinnard, Sarah E. Reed, Deanna Kerrigan, Maria L. Alcaide, Mardge H. Cohen, Oluwakemi Sosanya, Anandi N. Sheth, Adaora A. Adimora, Jennifer Cocohoba, Lakshmi Goparaju, Elizabeth T. Golub, Margaret Fischl & Lisa R. Metsch. (2020) Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women’s Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States. AIDS and Behavior 25:3, pages 667-678.
Crossref
Crossref
Herana Kamal Seneviratne, Allyson N. Hamlin, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y. Liu, Irene Kuo, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Adeola Adeyeye, Alex R. Rinehart, Marybeth McCauley, Joseph S. Eron, Myron S. Cohen, Raphael J. Landovitz, Craig W. Hendrix & Namandjé N. Bumpus. (2021) Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. ACS Pharmacology & Translational Science 4:1, pages 226-239.
Crossref
Crossref
Morgan M. PhilbinCarrigan ParishSadie BergenDeanna KerriganElizabeth N. KinnardSarah E. ReedMardge H. CohenOluwakemi SosanyaAnandi N. ShethAdaora A. AdimoraJennifer CocohobaLakshmi GoparajuElizabeth T. GolubMargaret FischlMaria L. AlcaideLisa R. Metsch. (2021) A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use. AIDS Patient Care and STDs 35:1, pages 23-30.
Crossref
Crossref
Andrew Gustin, Ross Cromarty, Luca Schifanella & Nichole R. Klatt. (2021) Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women. Seminars in Immunology 51, pages 101482.
Crossref
Crossref
Simone Perazzolo, Subhra Mandal, Pavan K. Prathipati & Christopher J. Destache. (2020) Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments. Frontiers in Pharmacology 11.
Crossref
Crossref
Lucile Pencolé, Minh P. Lê, Florian Bouchet-Crivat, Dominique Duro, Gilles Peytavin & Laurent Mandelbrot. (2020) Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model. AIDS 34:14, pages 2145-2149.
Crossref
Crossref
Tanmay A. Kulkarni, Aditya N. Bade, Brady Sillman, Bhagya Laxmi Dyavar Shetty, Melinda S. Wojtkiewicz, Nagsen Gautam, James R. Hilaire, Sruthi Sravanam, Adam Szlachetka, Benjamin G. Lamberty, Brenda M. Morsey, Howard S. Fox, Yazen Alnouti, JoEllyn M. McMillan, R. Lee Mosley, Jane Meza, Paul L. Domanico, Tai-Yuen Yue, Gary Moore, Benson J. Edagwa & Howard E. Gendelman. (2020) A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials 19:8, pages 910-920.
Crossref
Crossref
Jeffrey Kwong. (2020) New drug treatment options for HIV antiretroviral therapy. The Nurse Practitioner 45:3, pages 28-38.
Crossref
Crossref
Meredith E. Clement, Ryan Kofron & Raphael J. Landovitz. (2020) Long-acting injectable cabotegravir for the prevention of HIV infection. Current Opinion in HIV and AIDS 15:1, pages 19-26.
Crossref
Crossref
Joshua P Havens, Kimberly K Scarsi, Harlan Sayles, Donald G Klepser, Susan Swindells & Sara H Bares. (2019) Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States. Open Forum Infectious Diseases 6:10.
Crossref
Crossref
James R. Hilaire, Aditya N. Bade, Brady Sillman, Nagsen Gautam, Jonathan Herskovitz, Bhagya Laxmi Dyavar Shetty, Melinda S. Wojtkiewicz, Adam Szlachetka, Benjamin G. Lamberty, Sruthi Sravanam, Howard S. Fox, Yazen Alnouti, Prasanta K. Dash, JoEllyn M. McMillan, Benson J. Edagwa & Howard E. Gendelman. (2019) Creation of a long-acting rilpivirine prodrug nanoformulation. Journal of Controlled Release 311-312, pages 201-211.
Crossref
Crossref